Latest Anticoagulants Stories

ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Treating patients with the new blood thinning medication dabigatran (Pradaxa®), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime).The study will be presented today at the Academy of Managed Care Pharmacy's Educational Conference in Atlanta, Ga. Dabigatran is a type of blood-thinning medication used to...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantially less bleeding, and also results in lower mortality.  ahe benefits of apixaban are consistent irrespective of how well warfarin is used at different centers, as measure by “time in therapeutic range.” The randomized, double-blind clinical trial known...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in substantially less bleeding and also results in lower mortality. The results were presented by Duke University Medical Center researchers at the European Society of Cardiology in Paris, France, today, and published simultaneously online in the New England Journal of...

RIDGEFIELD, Conn., Aug. 26, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN(TM), a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.(1) The 12-week study will compare three doses of dabigatran etexilate (150mg bid, 220mg bid and 300mg bid) to warfarin in patients with both aortic valve replacements and mitral valve replacements.(1) A...

Patients with irregular heartbeat could benefit from a drug that is easier to administer than the current standard treatmentPatients with an irregular heart beat could benefit from a drug that is easier to administer than the current standard treatment.The condition, which is more common with older age and affects about 800,000 people in the UK, can lead to blood clots forming and significantly increases the risk of stroke.A global study, led by the University of Edinburgh and the Duke...

In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be an attractive alternative to warfarin, the current standard for treatment of atrial fibrillation.The full intention-to-treat analysis, which includes patients who discontinued study drug, showed that rivaroxaban was noninferior to warfarin for...

A pharmacist-directed anticoagulation service improves the coordination of care from the hospital to an outpatient clinic for patients treated with the anticoagulant drug warfarin, according to a Henry Ford Hospital study.The study, published online today in the July/August issue of the Journal of Hospital Medicine, found that the transition of care directed by the anticoagulation service was seamless in more than 70 percent of patients treated and risk of bleeding and thrombosis declined by...

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S. News & World Report's Best Hospitals 2011-2012, published online on July 19. PRADAXA is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in...

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer."This is the first prospective study to evaluate the...

CHICAGO, July 6, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: United Parcel Services (NYSE: UPS), FedEx Corporation (NYSE: FDX), Bayer (OTC: BAYRY) , Johnson & Johnson (NYSE: JNJ) and Sanofi-Aventis (NYSE: SNY). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...